Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and Prevention (CDC)[1]. With this statistic in mind, it’s no surprise that many people are curious about Ozempic,
Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food and Drug Administration has declared Novo Nordisk's blockbusters Ozempic and Wegovy are no longer in shortage.
An update to the FDA drug shortage list on Feb. 21 listed the semaglutide shortage as being resolved. In a press release, Novo Nordisk said it is shipping all doses of the medication regularly to ...
The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in stand-alone drug plans in recent years.
The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.